Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2000 5
2005 1
2007 2
2008 1
2009 1
2010 1
2013 1
2014 1
2015 4
2016 2
2017 2
2018 1
2019 3
2020 1
2021 1
2022 3
2023 1
2024 7
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings.
Zhang Y, Ren R, Yang L, Zhang H, Shi Y, Okhravi HR, Vitiello MV, Sanford LD, Tang X. Zhang Y, et al. Transl Psychiatry. 2022 Apr 1;12(1):136. doi: 10.1038/s41398-022-01897-y. Transl Psychiatry. 2022. PMID: 35365609 Free PMC article.
Polysomnography (PSG) studies of sleep changes in Alzheimer's disease (AD) have reported but not fully established the relationship between sleep disturbances and AD. ...
Polysomnography (PSG) studies of sleep changes in Alzheimer's disease (AD) have reported but not fully established the relationship b …
Towards cascading genetic risk in Alzheimer's disease.
Altmann A, Aksman LM, Oxtoby NP, Young AL; ADNI; Alexander DC, Barkhof F, Shoai M, Hardy J, Schott JM. Altmann A, et al. Brain. 2024 Aug 1;147(8):2680-2690. doi: 10.1093/brain/awae176. Brain. 2024. PMID: 38820112 Free PMC article.
Alzheimer's disease typically progresses in stages, which have been defined by the presence of disease-specific biomarkers: amyloid (A), tau (T) and neurodegeneration (N). ...Over the past decades, genome-wide association studies have implicated 90 different loci involved …
Alzheimer's disease typically progresses in stages, which have been defined by the presence of disease-specific biomarkers: amyloid ( …
Neuropsychiatric symptoms in cognitive decline and Alzheimer's disease: biomarker discovery using plasma proteomics.
Rabl M, Clark C, Dayon L, Popp J; Alzheimer’s Disease Neuroimaging Initiative. Rabl M, et al. J Neurol Neurosurg Psychiatry. 2024 Sep 17:jnnp-2024-333819. doi: 10.1136/jnnp-2024-333819. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39288961 Free article.
BACKGROUND AND OBJECTIVES: Neuropsychiatric symptoms (NPS) are common in older people with cognitive impairment and Alzheimer's disease (AD). No biomarkers to detect the related pathology or predict the clinical evolution of NPS are available yet. ...METHODS: A panel of 19 …
BACKGROUND AND OBJECTIVES: Neuropsychiatric symptoms (NPS) are common in older people with cognitive impairment and Alzheimer's disea …
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, Matthews BR, Miller DS, Mahinrad S, Napoli S, Okhravi HR, Petersen RC, Siemers ER, Weber CJ, Weisman DC, Carrillo MC. Rentz DM, et al. Alzheimers Dement. 2024 Nov;20(11):8162-8171. doi: 10.1002/alz.14199. Epub 2024 Sep 22. Alzheimers Dement. 2024. PMID: 39306695 Free PMC article.
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. ...HIGHLIGHTS: Effective communication of risks, benefits, bur …
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease ch …
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit. Wagemann O, et al. JAMA Neurol. 2024 Jun 1;81(6):582-593. doi: 10.1001/jamaneurol.2024.0991. JAMA Neurol. 2024. PMID: 38683602 Free PMC article. Clinical Trial.
Enhancing cognitive performance prediction by white matter hyperintensity connectivity assessment.
Petersen M, Coenen M, DeCarli C, De Luca A, van der Lelij E; Alzheimer’s Disease Neuroimaging Initiative; Barkhof F, Benke T, Chen CPLH, Dal-Bianco P, Dewenter A, Duering M, Enzinger C, Ewers M, Exalto LG, Fletcher EM, Franzmeier N, Hilal S, Hofer E, Koek HL, Maier AB, Maillard PM, McCreary CR, Papma JM, Pijnenburg YAL, Schmidt R, Smith EE, Steketee RME, van den Berg E, van der Flier WM, Venkatraghavan V, Venketasubramanian N, Vernooij MW, Wolters FJ, Xu X, Horn A, Patil KR, Eickhoff SB, Thomalla G, Biesbroek JM, Biessels GJ, Cheng B. Petersen M, et al. Brain. 2024 Dec 3;147(12):4265-4279. doi: 10.1093/brain/awae315. Brain. 2024. PMID: 39400198 Free PMC article.
Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab.
Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, Selvam S, Pal B, Keane PA, Bhatia B, Hamilton R; Moorfields Medical Retina Injection Service. Sim SY, et al. Ophthalmol Retina. 2025 Jan;9(1):22-30. doi: 10.1016/j.oret.2024.07.020. Epub 2024 Jul 30. Ophthalmol Retina. 2025. PMID: 39084554
Physician bias is inherent in these types of observational studies so a prospective, randomized, controlled trial is recommended to validate these findings. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the e …
Physician bias is inherent in these types of observational studies so a prospective, randomized, controlled trial is recommended to validate …
Functionally distinct pericyte subsets differently regulate amyloid-beta deposition in patients with Alzheimer's disease.
Bohannon DG, Long D, Okhravi HR, Lee SC, De Jesus CL, Neubert TA, Rostagno AA, Ghiso JA, Kim WK. Bohannon DG, et al. Brain Pathol. 2025 Mar;35(2):e13282. doi: 10.1111/bpa.13282. Epub 2024 Jun 27. Brain Pathol. 2025. PMID: 38932696 Free PMC article.
Although the concept that the blood-brain barrier (BBB) plays an important role in the etiology and pathogenesis of Alzheimer's disease (AD) has become increasingly accepted, little is known yet about how it actually contributes. ...
Although the concept that the blood-brain barrier (BBB) plays an important role in the etiology and pathogenesis of Alzheimer's disea …
The Risk of Sympathetic Ophthalmia after Vitreoretinal Surgery.
Anikina E, Wagner SK, Liyanage S, Sullivan P, Pavesio C, Okhravi N. Anikina E, et al. Ophthalmol Retina. 2022 May;6(5):347-360. doi: 10.1016/j.oret.2022.01.012. Epub 2022 Jan 31. Ophthalmol Retina. 2022. PMID: 35093583
Economics of Public Antibiotics Development.
Okhravi C. Okhravi C. Front Public Health. 2020 May 21;8:161. doi: 10.3389/fpubh.2020.00161. eCollection 2020. Front Public Health. 2020. PMID: 32509716 Free PMC article.
38 results